Velan Capital initiated active stake in Praxis Precision Medicines, Inc
Key Summary: On March 20, 2023, Velan Capital disclosed 9.9% and stated that it intended to engage in communications with the board and management team regarding opportunities to enhance stockholder value and improve corporate governance.
Market Cap: $58 million | Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.
On March 20, 2023, Velan Capital disclosed 9.9% and stated that it intended to engage in communications with the board and management team regarding opportunities to enhance stockholder value and improve corporate governance. Source
Member discussion